These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31674161)

  • 1. Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major Depressive Disorder: an Open-Label Pilot Study.
    Lee YJ; Lee GW; Seo WS; Koo BH; Kim HG; Cheon EJ
    J Korean Med Sci; 2019 Nov; 34(42):e287. PubMed ID: 31674161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy of Neurofeedback in Patients with Major Depressive Disorder: An Open Labeled Prospective Study.
    Cheon EJ; Koo BH; Choi JH
    Appl Psychophysiol Biofeedback; 2016 Mar; 41(1):103-10. PubMed ID: 26392114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
    Husain MI; Chaudhry IB; Husain N; Khoso AB; Rahman RR; Hamirani MM; Hodsoll J; Qurashi I; Deakin JF; Young AH
    J Psychopharmacol; 2017 Sep; 31(9):1166-1175. PubMed ID: 28857658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.
    Ninan PT; Shelton RC; Bao W; Guico-Pabia CJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():86-91. PubMed ID: 24096053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant.
    Jamieson C; Popova V; Daly E; Cooper K; Drevets WC; Rozjabek HM; Singh J
    Health Qual Life Outcomes; 2023 May; 21(1):40. PubMed ID: 37158911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interpersonal psychotherapy as add-on for treatment-resistant depression: A pragmatic randomized controlled trial.
    Souza LH; Salum GA; Mosqueiro BP; Caldieraro MA; Guerra TA; Fleck MP
    J Affect Disord; 2016 Mar; 193():373-80. PubMed ID: 26799332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mindfulness-based cognitive therapy (MBCT) versus the health-enhancement program (HEP) for adults with treatment-resistant depression: a randomized control trial study protocol.
    Eisendrath SJ; Gillung EP; Delucchi KL; Chartier M; Mathalon DH; Sullivan JC; Segal ZV; Feldman MD
    BMC Complement Altern Med; 2014 Mar; 14():95. PubMed ID: 24612825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial of Intensive Short-Term Dynamic Psychotherapy for treatment resistant depression: the Halifax Depression Study.
    Town JM; Abbass A; Stride C; Bernier D
    J Affect Disord; 2017 May; 214():15-25. PubMed ID: 28266318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial.
    Smith DJ; Sarris J; Dowling N; O'Connor M; Ng CH
    Nutr Neurosci; 2018 Apr; 21(3):224-228. PubMed ID: 28224818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial.
    Husain MI; Chaudhry IB; Rahman RR; Hamirani MM; Qurashi I; Khoso AB; Deakin JF; Husain N; Young AH
    Trials; 2015 Sep; 16():410. PubMed ID: 26374703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study.
    Sharma A; Barrett MS; Cucchiara AJ; Gooneratne NS; Thase ME
    J Clin Psychiatry; 2017 Jan; 78(1):e59-e63. PubMed ID: 27898207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial.
    Bergfeld IO; Mantione M; Hoogendoorn ML; Ruhé HG; Notten P; van Laarhoven J; Visser I; Figee M; de Kwaasteniet BP; Horst F; Schene AH; van den Munckhof P; Beute G; Schuurman R; Denys D
    JAMA Psychiatry; 2016 May; 73(5):456-64. PubMed ID: 27049915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with response after deep transcranial magnetic stimulation in a real-world clinical setting: Results from the first 40 cases of treatment-resistant depression.
    Feffer K; Lapidus KAB; Braw Y; Bloch Y; Kron S; Netzer R; Nitzan U
    Eur Psychiatry; 2017 Jul; 44():61-67. PubMed ID: 28545010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humanistic outcomes in treatment resistant depression: a secondary analysis of the STAR*D study.
    DiBernardo A; Lin X; Zhang Q; Xiang J; Lu L; Jamieson C; Benson C; Lee K; Bodén R; Brandt L; Brenner P; Reutfors J; Li G
    BMC Psychiatry; 2018 Oct; 18(1):352. PubMed ID: 30373547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Supplementary Cognitive-Behavioral Therapy for Pharmacotherapy-Resistant Depression: A Randomized Controlled Trial.
    Nakagawa A; Mitsuda D; Sado M; Abe T; Fujisawa D; Kikuchi T; Iwashita S; Mimura M; Ono Y
    J Clin Psychiatry; 2017; 78(8):1126-1135. PubMed ID: 28252882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of brain-derived neurotrophic factor are unchanged after transcranial direct current stimulation in treatment-resistant depression.
    Palm U; Fintescu Z; Obermeier M; Schiller C; Reisinger E; Keeser D; Pogarell O; Bondy B; Zill P; Padberg F
    J Affect Disord; 2013 Sep; 150(2):659-63. PubMed ID: 23664268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.